# Paricalcitol Improves Anemia of Inflammation

> **NCT02876211** · PHASE4 · TERMINATED · sponsor: **Hospital Son Espases** · enrollment: 19 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Paricalcitol
- **DRUG:** Epoetin beta
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02876211
- **Lead sponsor:** Hospital Son Espases
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2022-08
- **Final completion:** 2024-12
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Difficult inclusion of patients diagnosed with renal anemia in chronic hemodialysis patients without hyperparathyroidism.
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876211, "Paricalcitol Improves Anemia of Inflammation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02876211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*